PROTOQSAR 2000 SL

Their core work

PROTOQSAR is a Valencia-based SME specialized in computational toxicology — they build QSAR (Quantitative Structure-Activity Relationship) models that predict the toxicity of chemicals, nanomaterials, and cosmetics without animal testing. Their software platforms help companies comply with EU REACH regulation by computationally assessing whether substances are safe, replacing expensive and slow laboratory experiments. They combine artificial intelligence and machine learning with deep domain knowledge in pharmacology and chemical hazard assessment, serving both regulatory compliance needs and pharmaceutical/cosmetics R&D.

What they specialise in

How they've shifted over time

PROTOQSAR's early H2020 work (2016–2019) centered on fundamental cell death biology — participating in projects studying apoptosis, necroptosis, and protein complexes that induce cell death (EPIC, PROTECTED). From 2019 onward, they pivoted sharply toward applied computational toxicology, coordinating their own QSAR-focused projects (QSAREACH, Eco-CosmePharm, NanoQSAR, GenoQSAR) and joining large-scale AI-driven safety assessment initiatives like ONTOX. The trajectory is clear: they moved from contributing biological knowledge as a participant to leading the development of regulatory-grade computational prediction tools as a coordinator.

PROTOQSAR is moving toward AI-powered, animal-free toxicity prediction platforms aimed at regulatory compliance — expect them to deepen this niche as EU chemical safety rules tighten.

How they like to work

PROTOQSAR balances leadership and partnership roughly equally — they coordinated 4 of their 10 projects, all in their core QSAR domain, while joining 6 larger consortia as a specialist contributor. With 42 unique partners across 20 countries, they maintain a broad European network rather than relying on a fixed set of collaborators. This pattern suggests they are comfortable both driving focused SME-scale projects and plugging into large multi-partner research initiatives where they bring specific computational modeling expertise.

PROTOQSAR has built a wide network of 42 distinct partners across 20 countries, indicating strong pan-European connectivity for a 10-person-project SME. Their MSCA-RISE and MSCA-ITN participation suggests strong ties to academic research groups and international mobility networks.

What sets them apart

PROTOQSAR occupies a rare niche: they are one of few European SMEs that both understand the molecular biology of toxicity mechanisms AND build the computational models to predict them. This dual capability — wet-lab knowledge combined with in silico modeling — makes them a credible bridge between academic toxicology research and regulatory-ready software tools. For consortium builders, they bring REACH regulatory expertise that most academic partners lack, packaged in an agile SME that can move faster than large institutions.

Highlights from their portfolio

• ONTOX
  Their largest project (EUR 734K) focused on AI-based animal-free toxicity testing — signals their growing role in next-generation risk assessment at scale.
• NanoQSAR
  Coordinated project applying QSAR methods specifically to nanomaterial toxicity — a technically demanding niche where few SMEs operate.
• PANACHE
  Largest participation-role project (EUR 294K) targeting pannexin/connexin modulators for inflammation treatment — shows their reach into therapeutic applications beyond pure toxicology.